Tesla, Inc. (TSLA.US) is being investigated by the NHTSA for door handle problems.
Tesla is currently being investigated by the US automotive safety regulatory agency due to issues with the door handles on some Model Y vehicles, which could potentially trap occupants inside the car.
Tesla, Inc. (TSLA.US) is currently under investigation by the US car safety regulatory agency due to issues with the door handles of certain Model Y vehicles, which could potentially trap occupants inside. The National Highway Traffic Safety Administration (NHTSA) announced on Tuesday that they have initiated a "preliminary evaluation" of this issue. In this problem, the electronic door handles may lose power and become unusable. The investigation involves some 2021 Model Y vehicles.
It is worth noting that a few days ago, there were reports of this issue with Tesla, Inc. These reports revealed a series of incidents where individuals were unable to open the doors after a power loss, particularly after accidents, resulting in injuries or even death.
NHTSA stated: "The focus of this investigation is on the operability of the electronic door locks from the outside of the vehicle, as there is no manual way to open the door in these situations. The agency will continue to monitor related reports involving individuals being trapped due to being unable to open doors from the inside, and the Office of Defects Investigation (ODI) will take further action if necessary."
Related Articles

Health 160 (02656): Hong Kong public offering received 751.77 times oversubcribed, listing on September 17th.

JOIN-SHARE (01543) has entered into a business cooperation agreement with Zhongshan Financial Investment.
Jiangsu Hengrui Pharmaceuticals (01276): Injection SHR-1826, Adelbeli monoclonal antibody injection, Bevacizumab monoclonal antibody injection obtained drug clinical trial approval letter.
Health 160 (02656): Hong Kong public offering received 751.77 times oversubcribed, listing on September 17th.

JOIN-SHARE (01543) has entered into a business cooperation agreement with Zhongshan Financial Investment.

Jiangsu Hengrui Pharmaceuticals (01276): Injection SHR-1826, Adelbeli monoclonal antibody injection, Bevacizumab monoclonal antibody injection obtained drug clinical trial approval letter.